Neurology

Study may lead to the development of treatments for disorders with damaged myelin sheath.

Increased gut bacteria linked to inflammation among children with multiple sclerosis.

Patients taking mitoxantrone for multiple sclerosis found to have higher rates of breast and colorectal cancers and leukemia.

Patients administered mitoxantrone for multiple sclerosis carry higher rates of breast and colorectal cancers and leukemia.

Drug produced by medicinal plant Oldenlandia affinis may block the progression of multiple sclerosis.

Difficulties exist between neurologists and insurance companies in regards to multiple sclerosis treatment.

MS patients who use cognitive remediation training program showed improvement in neuropsychological tests.

MS patients have higher rates of many comorbidities except for high cholesterol.

Patients and neurologists have different experiences when providing information and adhering to disease modifying drugs for multiple sclerosis.

Natalizumab has been generally considered among the most effective treatments for relapsing-remitting multiple sclerosis.

Minimizing sedentary behavior offers potential benefits for people with multiple sclerosis.

Top news of the day from across the health care landscape.

Ocrelizumab shows potential treating both relapsing and primary progressive forms of multiple sclerosis.

Ocrelizumab shows potential treating both relapsing and primary progressive forms of multiple sclerosis.

Video game-based cognitive rehabilitation programs show promise in treating multiple sclerosis symptoms.

Zinbryta found to reduce cells that contribute to neurological injury caused by multiple sclerosis.

Study finds fewer exchange health plans are placing specialty drugs on the highest tier.

A recent Tecfidera study finds find no rate of relapse of progression in MS patients.

A recent Tecfidera study finds find no rate of relapse of progression in MS patients.

Optic neuropathy is common in multiple sclerosis as the immune system destroys myelin and damages the nerves.

Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells in MS patients.

A new treatment for MS was found effective in animal models.

Specially synthesized plant peptide cyclotide found to suppress onset of multiple sclerosis.

Top news of the day from across the health care landscape.

A large proportion of patients with multiple sclerosis experience taste deficits.